In this review, we focus on post-progression survival after first-line chemotherapy of advanced gastric cancer, and particularly the differences between Japan and the rest of the world. We reviewed 15 recent phase III trials of which 4 were solely recruited from Japanese and 11 from rest of the world. The patient characteristics age, performance status, previous gastrectomy and the number of metastatic sites were similar in Japan and rest of the world. However, the diffuse histological type was more common in Japan. While overall survival was longer in Japan (10.5-14.1 vs. 7.9-12.2 months), progression-free survival tended to be shorter in Japan (3.6-6.0 vs. 3.1-7.4 months). Postprogression survival calculated as the difference between median overall survival and progressionfree survival was clearly longer in Japan (6.9-8.6 vs. 2.4-6.2 months). The proportion of patients receiving second-line chemotherapy (%2nd-CX) was quite different in Japan and rest of the world (69-85% vs. 11-59%). Correlations between %2nd-CX and post-progression survival were strong (Spearman's rank correlation coefficient; ρ = 0.86, P < 0.001). Correlations between %2nd-CX and ratio of post-progression survival to total overall survival were also strong (ρ = 0.84, P < 0.001). Because a survival benefit of second-CX was documented in several phase III trials, it can be concluded that higher %2nd-CX partly contributed to extended post-progression survival. However, considering that second-CX increased survival only by~1.5 months at median, other factors such as third-line chemotherapy may have some influences to prolonged post-progression survival.
Introduction
Gastric cancer is one of the most prevalent malignancies worldwide (1) and although its incidence has been declining, it is still the fifth most common cancer globally. However, there are regional differences, and especially gastric cancer is more common in East Asia than in western countries (2) .
The standard treatment for advanced gastric cancer (AGC), including both metastatic and recurrent disease, is palliative chemotherapy. Phase III trials showed that palliative first-line chemotherapy resulted in a survival benefit relative to best supportive care (3) (4) (5) (6) . The most widely accepted first-line chemotherapy regimen is a combination of fluoropyrimidine (i.e. 5-fluorouracil, capecitabine or S-1) plus platinum (i.e. cisplatin or oxaliplatin) with or without trastuzumab according to human epidermal growth factor receptor type2 (HER2) status (7) . Some regional differences in overall survival (OS) were reported from the recent global phase III trials of AGC; it was found that the Japanese subgroup tended to survive longer than others, even though the progression-free survival (PFS) was similar. For example, the Avastin in Gastric Cancer (AVAGAST) study (8) , an international phase III trial investigating the survival benefit of bevacizumab added to doublet chemotherapy with 5-fluorouracil or capecitabine plus cisplatin (FP) as first-line chemotherapy, reported that the Asian subgroup (of which 50% were registered from Japan) experienced longer survival than the European and Pan-American subgroups. The median survival times (MST) in the fluoropyrimidine plus cisplatin arm were 12.1 months in Asian, 8.6 months in European and 6.8 months in Pan-American cohorts. On the other hand, median PFS in the fluoropyrimidine plus cisplatin arm were not very different among the three groups, namely 5.6 months in Asian, 4.4 months in European and 4.4 months in Pan-American cohorts. Similarly, the Trastuzumab for Gastric Cancer (ToGA) study (9) , which is another global phase III trial comparing FP with and without trastuzumab as first-line chemotherapy for HER2-positive AGC, also showed that OS of the Japanese subgroup (10) was longer than in the other groups; MST in the capecitabin plus cisplatin arm was 17.7 months in Japanese and 11.1 months for all patients. On the other hand, median PFS was very similar at 5.6 months in Japanese and 5.5 months for all patients. From these results, it seems that differences in postprogression survival (PPS) after first-line chemotherapy are greater than differences in PFS, which can be attributed to the greater efficacy of the first-line chemotherapy.
In this review article, we evaluate the difference between Japan and rest of the world (ROW), focusing on survival after the failure of first-line chemotherapy in AGC.
Selection of clinical trials
The trials included in this review were selected according to the following criteria: (i) phase III trial of first-line chemotherapy for gastric or gastroesophageal junction adenocarcinoma, (ii) metastatic or recurrent disease, (iii) reporting both OS and PFS, (iv) published 2007-15 in English or presented at annual conferences of the American Society of Clinical Oncology or the European Society of Medical Oncology 2013-15. Global studies for which patients were registered from both Japan and ROW were excluded because it was difficult to distinguish the results for patients from different locations. A total of 15 phase III trials with 33 treatment arms were then included in this review; (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) four trials with nine treatment arms were registered for patients solely from Japan (Japanese trials) and 11 trials with 24 treatment arms from ROW (non-Japanese trials) ( Table 1 ). Four of the nine treatment arms investigated in Japanese trials were monotherapies, whereas all treatment arms in ROW consisted of doublet or triplet regimens. This is because the standard treatment in Japan was fluoropyrimidine monotherapy before the JCOG 9912 trial and SPIRITS were published in 2007. Thereafter, Japanese standard treatment changed from fluoropyrimidine monotherapy to a fluoropyrimidine plus platinum doublet regimen, which was adopted as the control arm in the following global phase III trials in which Japan participated (26) . In these selected recent phase III trials, baseline characteristics, PFS, OS, PPS and the proportion of patients receiving post chemotherapy were compared between Japanese and non-Japanese clinical trials.
Statistical analysis
We defined the PPS as the difference between median OS and median PFS in each trial arm. We calculated the ratio of PPS in OS (PPS/OS) for each trial arm as median PFS divided by median OS. To assess the relation between PPS and either proportion of second-line chemotherapy and PPS/OS, we used Spearman's rank correlation coefficient by SPSS version 23.0 (SPSS, Inc., Chicago, IL, USA).
Patients' characteristics
Patients' characteristics such as age, performance status, prior gastrectomy and number of metastatic sites were similar in the Japanese and non-Japanese trials. However, diffuse type was more common in the Japanese trials (56% vs. 38%) ( Table 1 ). This could be due to differences in tumor location, as it is well known that primary tumors of Asian gastric cancer patients are located predominantly in the lower part of the stomach while those in western patients are more often in the upper part of the stomach or at the GE-junction (27) . Information on other prognostic factors such as ALP (28, 29) could not be extracted from the reports assessed here.
OS, PFS and PPS
As recently pointed out, survival times seem to be longer in Japanese trials than others (10.4-14.1 vs. 7.9-12.2 months), while median PFS tends to be shorter in Japan (3.6-6.0 vs. 3.1-7.4 months) ( Table 2 and Fig. 1 ). One possible reason for shorter PFS in Japan is differences in treatment regimens. Limiting the analysis to doublet regimens, median PFS was in fact found to be very similar between Japanese and non-Japanese (4.8-6.0 months with 5 treatment Considering that patients' background such as PS and numbers of metastatic sites before first-line chemotherapy were similar in the Japanese and ROW trials, it can be suggested that the differences in PPS following similar PFS may be caused by factors other than patient background at the initiation of first-line chemotherapy.
Second-line chemotherapy
Because survival benefits of second-line chemotherapy for AGC compared with best supportive care (Table 3) were documented in several phase III trials conducted outside Japan, subsequent treatment after the failure of first-line chemotherapy is considered to be one of the major factors affecting PPS (32) (33) (34) (35) . Indeed, the fraction of patients receiving second-line chemotherapy is quite different in Japanese and non-Japanese clinical trials (69-85% vs. 11-59%). Figure 2a shows the correlation between the proportion of patients receiving second-line chemotherapy and PPS. While Japanese and non-Japanese trials appear clearly separated, the proportion of patients receiving second-line chemotherapy and PPS is strongly correlated (ρ = 0.86, P < 0.001). Moreover, Fig. 2b shows the strong correlation between the proportion of patients receiving second-line chemotherapy and ratio of PPS to total OS, which is also strongly correlated (ρ = 0.84, P < 0.001). Japanese and nonJapanese trials were also clearly different in this respect. These results indicate that the higher proportion of patients receiving second-line chemotherapy in Japanese trials is likely to be the most influential factor for longer PPS in Japanese than non-Japanese trials.
Third-line chemotherapy
Although the survival benefit of second-line chemotherapy was documented in several phase III trials, this benefit calculated as the difference in MST between patients on chemotherapy and those on best supportive care, was as little as 1.4-1.6 months. This minor survival advantage does not explain the substantial difference in PPS in the Japanese and non-Japanese trials (6.9-8.6 vs. 2.4-6.2 months). Therefore, it is likely that there are reasons other than second-line chemotherapy deployment for longer PPS in Japanese trials. One possible reason may be third-line chemotherapy. Because there has been no clear evidence of a survival benefit from third-line chemotherapy, it is not commonly used outside Japan. The subgroup analysis of Japanese and western patients in RAINBOW study, which is a global phase III trial of paclitaxel with or without ramucirumab (RAM) as second-line chemotherapy, also suggested the survival benefit of third-line chemotherapy. In that manuscript, OS of Japanese group was longer than that of western population (PTX arm: 11.5 months vs. 5.9 months, RAM+PTX arm: 11.4 months vs. 8.6 months). And the rate of post-discontinuation therapy was higher in the Japanese population (75.0%) than in the western population (37.2%).
While the National Comprehensive Cancer Network guidelines for gastric cancer (ver.3. 2016) do not refer to third-line chemotherapy, Japanese gastric cancer treatment guidelines 2014 (ver.4) (36) do recommend it. This is based on the results of the WJOG4007 trial (37), a Japanese phase III trial comparing weekly paclitaxel and irinotecan as second-line chemotherapy for AGC patients refractory to treatment with fluoropyrimidine plus platinum. For OS, both arms seemed to yield better results than in non-Japanese trials of second-line chemotherapy (9.5 months in the paclitaxel arm and 8.4 months in the irinotecan arm). In the WJOG4007 trial, the majority Table 2 .
of patients received third-line chemotherapy (89.8% in the paclitaxel arm and 72.1% in the irinotecan arm), and the survival curves of the subset who received crossover treatments between weekly paclitaxel and irinotecan as the second-and third-line treatments overlapped completely regardless of the sequence. Therefore, it can be suggested that third-line chemotherapy may have contributed to prolonged OS. Similar to the treatment strategy which recommended the use of all active cytotoxic drugs for metastatic colorectal cancer (38) , it is proposed that all available active drugs, namely, fluoropyrimidine, platinum, taxane and irinotecan should be deployed in strategies for treating AGC.
Problems caused by the regional difference in PPS
It is difficult to show additional benefits of newly developed drugs such as molecular targeting agents as first-line chemotherapy in clinical trials with the primary endpoint of OS if the PPS is prolonged by subsequent treatments, considering that differences in PFS (direct efficacy of the chemotherapy) are much smaller than those in PPS between Japanese and non-Japanese clinical trials. The influence of longer PPS on the merit in PFS for OS was reported by Broglio and Berry. They showed that a statistical benefit in PFS will likely be lost in OS when the median PPS is moderate, and very likely lost when the median PPS is large (39) . Indeed, in the AVAGAST trial, longer PPS resulted in the higher hazard ratio of OS for the Japanese subset than ROW based on the similar PFS of the test arm in the two groups (40).
These results suggest two issues to be taken into account for developing new drugs for AGC. One is to conduct clinical trials separately for Japanese and non-Japanese populations, and the other is setting the limitation of the number of patients enrolled from Japan as small as possible. Although these development strategies may be considered efficacious for winning drug approval, there are some associated problems, such as high costs and delays. More importantly, better survival of Japanese patients in clinical trials and Japanese subsets in global trials suggests that Japanese treatment approaches using all available active drugs over the whole course of treatment may maximize the clinical benefit also to non-Japanese AGC patients if adopted worldwide.
Limitations
Although relationships between PPS and the proportion of patients receiving second-line chemotherapy are the main topics of this review, there are some limitations to the analysis presented. First, prognostic factors such as performance status at the time of disease progression during first-line chemotherapy could not be adjusted. Since patient's characteristic just before second-line chemotherapy which might contribute difference in PPS in Japan and ROW are not available. Therefore, a possible alternative explanation for longer PPS in Japan is that this is the result of patient selection although there were no remarkable differences in patient background at the initiation of the first-line chemotherapy. Second, we could not evaluate the difference of tumor burden between Japan and ROW. Nishina et al. (40) reported the subgroup analysis of Japanese patients and ROW patients of AVAGAST trial. They concluded that the small tumor burden associated with earlier time of diagnosis and frequent use of second-line chemotherapy in Japan might be one explanation for regional outcome differences. Third, we calculated PPS with median OS minus PFS. This calculation is just a rough estimation. Some patients were censored due to treatment discontinuation during first-line chemotherapy in PFS analysis or being alive at the time of OS analysis. Fourth, the sample size in each clinical trial was not considered in the analysis. Statistical testing to adjust for sample size was not performed when comparing the differences of OS, PFS and PPS between Japanese and non-Japanese trials. Furthermore, biological differences including immune system factors that might differ between Japanese and non-Japanese gastric cancer patients are not yet understood.
Conclusions
In clinical trials of first-line chemotherapy for AGC, longer OS of Japanese than non-Japanese patients may be primarily due to longer post-progression survival in Japan. Because of the similar PFS in Japanese and non-Japanese patients, this survival advantage may be the result of the higher proportion of patients receiving subsequent chemotherapy in Japan. It is expected that these disparities can be diminished in the near future by global collaboration.
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